ArticleCellular oncology (Dordrecht, Netherlands)2025
Upregulated NNMT sustains angiogenesis in clear cell renal cell carcinoma through activation of the SDF-1/CXCR4-ERK-CCL20 axis.
Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundNicotinamide N-methyltransferase (NNMT) is involved in the development of several cancers. Tumor stem cells are present in various cancers and are linked to treatment resistance, tumor recurrence, and metastasis. However, the role of NNMT in regulating the stemness characteristics of clear cell renal cell carcinoma (ccRCC) is not yet fully understood.
methodsNNMT expression was identified as differentially expressed through the analysis of TCGA and GEO datasets (GSE105261 and GSE66272). Functional significance was explored using xenograft models. We performed qPCR, western blot, enzyme-linked immunosorbent assay (ELISA) and additional assays to examine the effects of NNMT on ccRCC stem cells. The potential molecular mechanism of ccRCC stem cells in promoting angiogenesis was investigated through RNA-seq analysis. The expression of C-C motif chemokine ligand 20 (CCL20) was validated through western blot and ELISA analyses. Regulation of angiogenesis was assessed using tube formation assays and Matrigel plug assays.
resultsNNMT was significantly upregulated in ccRCC tumor tissues and impaired the prognosis in ccRCC patients. In vivo studies revealed that NNMT depletion significantly inhibited tumor growth, whereas increased NNMT levels enhanced tumor progression. Additionally, NNMT enhanced the stemness characteristics of ccRCC cells and maintained C-X-C chemokine receptor type 4 (CXCR4) expression through the activation of Signal Transducer and Activator of Transcription 3 (STAT3) phosphorylation. Moreover, NNMT facilitated the recruitment and differentiation of ccRCC stem cells towards endothelial cells via the stromal cell–derived factor 1 (SDF-1)/CXCR4 axis, thereby promoting vessel function and tumor growth.
conclusionNNMT functions as an oncogene, strengthening the stemness properties of ccRCC cells and sustaining angiogenesis. These results indicate that NNMT may be a viable therapeutic target and prognostic biomarker for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.